Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Cancer care

Sort by: Newest first Oldest first A-Z Z-A

  • Digitalised illustration of DNA in pill representing personalised medicine

    Genomic medicine is going mainstream and pharmacists need to be prepared Subscription

    The 100,000 Genome Project is driving the move from a ‘one size fits all’ approach to treatment, towards personalised, or precision, medicine. Genetic information is also being used by pharmaceutical companies to help speed up drug discovery and development, and reduce the associated costs. Pharmacists will have an important role to play when genomic medicine goes mainstream.

  • Andrew Godfrey running

    Multiple myeloma: an expensive revolution Subscription

    New treatments for this rare form of cancer have transformed patient survival rates, but the benefits have come with huge costs.

  • Micrograph of multiple myeloma tumour cells (green) and bone cells (red) growing on a scaffold made of silk protein (purple), designed to resemble bone material

    Multiple myeloma: pharmacological management

    Although multiple myeloma is currently regarded as being incurable in the majority of patients, the outlook for patients diagnosed with the condition has improved markedly over the last 40 years, with survival rates quadrupling. Significant advances in both treatment and supportive therapies have contributed to these improved outcomes and are discussed in this article.

  • Photopharmacology concept with light spectrum and switch

    Photopharmacology: using light to activate drugs Subscription

    Drugs that contain synthetic light-switching molecules could help target therapies to particular parts of the body, limiting side effects. Researchers have started using this approach to tackle blindness, cancer, diabetes, and antibiotic resistance, but questions remain about the clinical practicality of the field.

  • Patients with cancer and cancer survivors have an increased risk of adverse cardiovascular outcomes, including left ventricular (LV) dysfunction, heart failure (HF) and acute coronary syndromes.

    Cardiovascular side effects of cancer treatments Subscription

    The cardiovascular side effects of cancer treatments remain a challenge in oncologic care. Patients with cancer and cancer survivors have an increased risk of adverse cardiovascular outcomes, including left ventricular (LV) dysfunction, heart failure (HF) and acute coronary events. The treatments most frequently associated with cardiovascular side effects include anthracyclines, monoclonal antibodies (mAbs) targeting the HER2 pathway, and small molecule tyrosine kinase inhibitors (TKIs), ...

  • Micrograph of a group of tumor-specific T cells attacking a tumor cell

    T-cell therapies for cancer: from outsider to pharmaceutical darling Subscription

    Less than a decade ago, work on T-cell therapies by a handful of researchers was snubbed by their peers but now the field has exploded, money has poured in and there is a race on to see who can bring the technology to patients the quickest.

  • 3D MRI scan of a breast with breast cancer

    Improving long-term adjuvant anti-oestrogenic therapy for breast cancer Subscription

    Long-term (five years) adjuvant tamoxifen treatment for oestrogen receptor-positive, or ER-positive, breast cancer post-surgery is recognised as a major advance in healthcare. Clinical trials comparing standard and extended tamoxifen therapy found a major decrease in mortality occurred in the ten years following a decade of adjuvant therapy. Studies in premenopausal breast cancer patients showed that ovarian function suppression (OFS) plus an aromatase inhibitor (AI), ...

  • Close up of kidney with renal cell carcinoma

    Mammalian target of rapamycin (mTOR) inhibitors in solid tumours Subscription

    The phosphatidylinositol-3-kinase /protein kinase B/mammalian target of rapamycin (PI3K/AKT/mTOR) pathway plays an important role in cell proliferation, growth, and angiogenesis. mTOR is a critical signalling protein as it serves as precursor to many pathways related to cell growth and survival. When this major pathway is dysregulated, it can cause uninhibited activation of cancer cell growth and proliferation. This commonly results in malignancies that affect the kidney, breast and ...

  • Micrograph of acute myeloid leukaemia (AML)

    Current treatments and future targeted treatments for acute myeloid leukaemia Subscription

    While the initial therapy for acute myeloid leukaemia (AML) treatment is relatively standardised, the high incidence of refractory/relapsed disease remains a great challenge. Progress has been made in understanding the pathophysiology of both initial and recurrent disease phases, leading to rigorous pre-clinical studies to identify and selectively target cellular pathways that promote leukaemogenesis. In this article, we discuss the ongoing efforts in overcoming relapsed disease, through ...

  • Five clocks, similar to time zone clocks, indicating different patients symbolising the concept of chronotherapy

    Cancer chronotherapy: timing drug administration to optimise efficacy and reduce toxicity Subscription

    Oncologist Francis Lévi has been probing the potential of chronotherapy for 20 years, but momentum is now building as more researchers join his mission to prove that the time cancer drugs are given influences their efficacy and toxicity.

Show  10 per page20 per page50 per page

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.